Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This commentary was funded by Amgen.

Declaration of financial/other relationships

JD is a consultant/advisor for Precision Health Economics & Amgen. JPM is an employee of Precision Health Economics, a research consulting firm owned by Precision Medicine Group and compensated by Amgen to conduct the study. Peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no other relevant financial relationships to disclose.

Acknowledgments

The authors would like to thank the three anonymous reviewers for their thoughtful feedback and input on the manuscript.